Crude peptide: difference between revisions
Diff·revision 9 → 10·14:29, 2 Jan 2025
Difference between revision 9 and revision 10 of Crude peptide. 12 lines changed; the page grew by 686 bytes.
| Revision 9 — 02:33, 15 Dec 2024 TitrationTheo (talk) convert a hard-coded date to the house format 2,632 bytes ±0 | Revision 10 — 14:29, 2 Jan 2025 SarcopeniaSefa (talk) add category for logistics 3,318 bytes +686 | ||
|---|---|---|---|
| 1 | {{Infobox concept | 1 | {{Infobox concept |
| 2 | | name = Crude peptide | 2 | | name = Crude peptide |
| + | 3 | | subtitle = Process intermediate | |
| 3 | | Obtained from = [[Resin cleavage|Cleavage]] of the assembled chain | 4 | | Obtained from = [[Resin cleavage|Cleavage]] of the assembled chain |
| 4 | | Typical purity = Highly variable; sequence-dependent | 5 | | Typical purity = Highly variable; sequence-dependent |
| ⋮ | ⋮ | ||
| 19 | Non-peptide material is present too: scavengers, residual cleavage reagent, and trifluoroacetate. A crude figure quoted as a percentage is normally a chromatographic [[Area percent purity|area percent]], so it says nothing about how much of the solid is peptide at all. See [[Peptide content]].{{r|usp1503}} | 20 | Non-peptide material is present too: scavengers, residual cleavage reagent, and trifluoroacetate. A crude figure quoted as a percentage is normally a chromatographic [[Area percent purity|area percent]], so it says nothing about how much of the solid is peptide at all. See [[Peptide content]].{{r|usp1503}} |
| 20 | 21 | ||
| + | 22 | == From crude to purified == | |
| + | 23 | [[Preparative HPLC purification|Preparative chromatography]] separates the target from the closely related impurities, and the yield of that step falls as crude purity falls: more material must be discarded to reach a given specification.{{r|behrendt2016}} | |
| + | 24 | ||
| + | 25 | |+ How crude purity governs the purification burden{{r|usp621}} | |
| + | 26 | | Crude purity | Consequence for purification | | |
| + | 27 | |---|---| | |
| + | 28 | | High | Narrow fraction cut; good recovery | | |
| + | 29 | | Moderate | Wider separation problem; recovery falls | | |
| + | 30 | | Low | Several passes may be required | | |
| + | 31 | ||
| 21 | == References == | 32 | == References == |
| 22 | {{reflist}} | 33 | {{reflist}} |
| ⋮ | ⋮ | ||
| 24 | <ref name="usp1503">United States Pharmacopeia, General Chapter <1503>, ''Quality Attributes of Synthetic Peptide Drug Substances''.</ref> | 35 | <ref name="usp1503">United States Pharmacopeia, General Chapter <1503>, ''Quality Attributes of Synthetic Peptide Drug Substances''.</ref> |
| 25 | <ref name="merrifield1963">Merrifield RB. "Solid phase peptide synthesis. I. The synthesis of a tetrapeptide." ''Journal of the American Chemical Society'' 85(14):2149–2154 (1963). DOI:10.1021/ja00897a025.</ref> | 36 | <ref name="merrifield1963">Merrifield RB. "Solid phase peptide synthesis. I. The synthesis of a tetrapeptide." ''Journal of the American Chemical Society'' 85(14):2149–2154 (1963). DOI:10.1021/ja00897a025.</ref> |
| + | 37 | <ref name="usp621">United States Pharmacopeia, General Chapter <621>, ''Chromatography''.</ref> | |
| 26 | 38 | ||
| 27 | {{DEFAULTSORT:Crude peptide}} | 39 | {{DEFAULTSORT:Crude peptide}} |